From this point of view, the activation of the cyclic GMP–AMP synthase (cGAS)–stimulator of interferon genes (STING) pathway to induce an inherent type I interferon (IFN) response has received increasing attention as the next generation of cancer immunotherapy [8,9,10]. Here, STING1 is linked to cancer.